Historical position

Goldman Sachs Group Inc.’s Edwards Lifesciences Corp (EW) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Goldman Sachs Group Inc.Verified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2016Earliest verified positive filing snapshot
Latest statusHistorical positionBased on the latest supported relationship state
Peak shares5.58MHighest verified quarter-end share count
Quarters reported16Verified quarters with shares above zero
What happened?

Goldman Sachs Group Inc. first reported Edwards Lifesciences Corp in Q3 2016. The reported position was increased and reduced across later filings. Verified positive position history runs through Q3 2024. The current relationship status cannot be determined reliably from supported data.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q3 2024
Sold 19.7% of the position−790.19K shares · 3.21M shares remained
Filing context

Quarter-end price $65.99

Q3 2023
Sold 26.7% of the position−1.26M shares · 3.46M shares remained
Filing context

Quarter-end price $69.28

Q2 2023
Sold 0.4% of the position−16.82K shares · 4.72M shares remained
Filing context

Quarter-end price $94.33

Q1 2023
Bought 38.2% more+1.31M shares · 4.74M shares reported after the change
Filing context

Quarter-end price $82.73

Q4 2022
Bought 5.1% more+166.70K shares · 3.43M shares reported after the change
Filing context

Quarter-end price $74.61

Q2 2022
Bought 20.2% more+506.63K shares · 3.01M shares reported after the change
Filing context

Quarter-end price $0.10

Portfolio importance

How important was Edwards Lifesciences Corp in Goldman Sachs Group Inc.’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight0.0%Q3 2024
Last reported rank#495Rank unavailable
Peak portfolio weight0.1%Q1 2020
Best historical rank#147Q1 2020
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest filing quarter-end price$65.99Q3 2024

Derived from validated reported value and shares where supported.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

Coverage is bounded to the institution’s top reported positions and material events rather than every security in each Form 13F. Source filings may contain additional securities, and 13F filings do not reveal exact trade dates or execution prices.